🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEDOPI

    Ningbo Cancer Hospital

    Platinum sensitive recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEMOZOLOMIDE, TEMOZOLOMIDE

    Fondazione Telethon ETS

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TransCon TLR7/8 Agonist

    Lacuna Pharma Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion, evorpacept

    Wuhan Createrna Science and Technology Co., Ltd

    metastatic or unresectable, recurrent HNSCC

    phase 2 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun

    Philogen S.p.A.

    Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy

    phase 2 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion., MK-3120, ENFORTUMAB VEDOTIN

    Merck Sharp and Dohme

    Urothelial carcinoma

    phase 2 small molecule active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion., PARACETAMOL , CISPLATIN , FLUOROURACIL , -, MK-2870, CALCIUM FOLINATE , CALCIUM LEVOFOLINATE , -, MK-2870, -

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  9. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Disc Medicine

    Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

    phase 2 small molecule active

    1 trial

  10. Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1,200 mg concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  11. Kapruvia 50 micrograms/mL solution for injection

    Fresenius Kabi Australia Pty Limited

    Pruritus, Chronic Kidney Diseases

    phase 2 small molecule active

    1 trial

  12. Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThe

    Kyverna Therapeutics

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  13. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

  14. LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules

    Eisai Co.,

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  15. LENVIMA 4 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    advanced stage hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  16. LEVOFOLINATE DE CALCIUM ZENTIVA 10 mg/ml, solution injectable (IM/IV), Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Bemarituzumab, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ACCORD 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  17. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    basal cell carcinoma

    phase 2 small molecule active

    1 trial

  18. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Cutaneous squamous cell carcinoma (ccSCC)

    phase 2 small molecule active

    1 trial

  19. LIBTAYO 350 mg concentrate for solution for infusion., Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  20. LIBTAYO 350 mg concentrate for solution for infusion., IMUNOCARE 5% crema

    The George Institute

    Cutaneous Basal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  21. LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., REGN10597

    Lacuna Pharma Pty Ltd

    Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  22. LIBTAYO 350 mg concentrate for solution for infusion., M1774, M1774, M1774

    Merck Sharp and Dohme

    Non-Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. LIBTAYO 350 mg concentrate for solution for infusion., THIO

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. LIBTAYO 350 mg concentrate for solution for infusion., Vidutolimod, Vidutolimod

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources